Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

BACKGROUND: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. MATERIAL AND METHODS: We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordenskjöld, Anna, Fohlin, Helena, Rosell, Johan, Bengtsson, Nils-Olof, Fornander, Tommy, Hatschek, Thomas, Lindman, Henrik, Malmström, Per, Rydén, Lisa, Wallgren, Arne, Stål, Olle, Nordenskjöld, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400913/
https://www.ncbi.nlm.nih.gov/pubmed/37517154
http://dx.doi.org/10.1016/j.breast.2023.07.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400913/
https://www.ncbi.nlm.nih.gov/pubmed/37517154
http://dx.doi.org/10.1016/j.breast.2023.07.010

Ejemplares similares